Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001897612-25-000208
Filing Date
2025-05-14
Accepted
2025-05-14 10:47:09
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5694
  Complete submission text file 0001897612-25-000208.txt   7326
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Subject) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88586 | Film No.: 25943465
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1307 POINT STREET BALTIMORE MD 21231
Business Address 1307 POINT STREET BALTIMORE MD 21231 000-000-0000
T. Rowe Price Investment Management, Inc. (Filed by) CIK: 0001897612 (see all company filings)

EIN.: 854328500 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SCHEDULE 13G